Baxter International Inc.
BAX Healthcare Medical Instruments & Supplies
Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.
Follow BAX
Baxter International Inc. (BAX) EBITDA
Baxter International Inc.'s EBITDA for fiscal 2025 was $1.4B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $1.5B. Over the past ten years it has ranged from $1.2B (fiscal 2015) to $2.6B (fiscal 2019); the current reading is higher than 27% of that period. Baxter International Inc. ranks 7th of 50 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $1.4B | (2.56%) |
| FY2024 | $1.5B | (12.12%) |
| FY2023 | $1.7B | 22.27% |
| FY2022 | $1.4B | (37.62%) |
| FY2021 | $2.2B | (9.73%) |
| FY2020 | $2.5B | (5.25%) |
| FY2019 | $2.6B | 10.06% |
| FY2018 | $2.4B | 15.55% |
| FY2017 | $2.0B | 31.91% |
| FY2016 | $1.5B | 27.90% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $456.0M | 50.50% |
| Mar 2026 | $303.0M | 5.94% |
| Dec 2025 | $286.0M | (30.07%) |
| Sep 2025 | $409.0M | (8.71%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SOLV Solventum Corporation compare | $2.6B |
| BAX Baxter International Inc. | $1.5B |
| COO The Cooper Companies, Inc. compare | $928.2M |
| WST West Pharmaceutical Services, Inc. compare | $861.8M |
| ALGN Align Technology, Inc. compare | $802.0M |
| ATR AptarGroup, Inc. compare | $784.6M |
| BLCO Bausch + Lomb Corporation compare | $749.0M |
| RGEN Repligen Corporation compare | $161.0M |
| AVTR Avantor, Inc. compare | $124.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on BAX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement